Rift Valley fever; accidental infections among laboratory workers - PubMed (original) (raw)

• PMID: 18153372

Rift Valley fever; accidental infections among laboratory workers

K C SMITHBURN et al. J Immunol. 1949 Jun.

No abstract available

PubMed Disclaimer

Similar articles

• [ANIMAL HEPATO-NEUROTROPIC VIRAL INFECTIONS AND HUMAN VIRAL HEPATITIS. COMPARATIVE PATHOLOGICAL NOTE].
  PLACIDI L, ROUSSEL A. PLACIDI L, et al. Rev Hyg Med Soc. 1964 Apr-May;12:273-86. Rev Hyg Med Soc. 1964. PMID: 14147320 Review. French. No abstract available.
• [Inhibition of multiplication of virus in Rift Valley fever by homologous virus irradiated with ultraviolet rays. II].
  SAWA I. SAWA I. C R Seances Soc Biol Fil. 1956 Sep 10;150(4):835-7. C R Seances Soc Biol Fil. 1956. PMID: 13365226 French. No abstract available.
• [Study on DNA immune of envelope protein gene of Rift Valley Fever Virus].
  Wang QH, Wang XJ, Hu S, Ge JY, Bu ZG. Wang QH, et al. Wei Sheng Wu Xue Bao. 2007 Aug;47(4):677-81. Wei Sheng Wu Xue Bao. 2007. PMID: 17944371 Chinese.
• Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.
  Terasaki K, Tercero BR, Makino S. Terasaki K, et al. Virus Res. 2016 May 2;216:55-65. doi: 10.1016/j.virusres.2015.05.012. Epub 2015 May 27. Virus Res. 2016. PMID: 26022573 Free PMC article. Review.
• Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
  Rissmann M, Ulrich R, Schröder C, Hammerschmidt B, Hanke D, Mroz C, Groschup MH, Eiden M. Rissmann M, et al. Vaccine. 2017 Jan 23;35(4):655-662. doi: 10.1016/j.vaccine.2016.12.003. Epub 2016 Dec 21. Vaccine. 2017. PMID: 28012779

Cited by

• Humoral immunity to phlebovirus infection.
  Doores KJ. Doores KJ. Ann N Y Acad Sci. 2023 Dec;1530(1):23-31. doi: 10.1111/nyas.15080. Epub 2023 Nov 7. Ann N Y Acad Sci. 2023. PMID: 37936483 Free PMC article. Review.
• Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development.
  Reed C, Lin K, Wilhelmsen C, Friedrich B, Nalca A, Keeney A, Donnelly G, Shamblin J, Hensley LE, Olinger G, Smith DR. Reed C, et al. PLoS Negl Trop Dis. 2013 Apr 4;7(4):e2156. doi: 10.1371/journal.pntd.0002156. Print 2013. PLoS Negl Trop Dis. 2013. PMID: 23593523 Free PMC article.
• Clinical manifestations of Rift Valley fever in humans: Systematic review and meta-analysis.
  Anywaine Z, Lule SA, Hansen C, Warimwe G, Elliott A. Anywaine Z, et al. PLoS Negl Trop Dis. 2022 Mar 25;16(3):e0010233. doi: 10.1371/journal.pntd.0010233. eCollection 2022 Mar. PLoS Negl Trop Dis. 2022. PMID: 35333856 Free PMC article.
• Incubation periods of mosquito-borne viral infections: a systematic review.
  Rudolph KE, Lessler J, Moloney RM, Kmush B, Cummings DA. Rudolph KE, et al. Am J Trop Med Hyg. 2014 May;90(5):882-91. doi: 10.4269/ajtmh.13-0403. Epub 2014 Mar 17. Am J Trop Med Hyg. 2014. PMID: 24639305 Free PMC article. Review.
• Rift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model.
  Dodd KA, McElroy AK, Jones TL, Zaki SR, Nichol ST, Spiropoulou CF. Dodd KA, et al. PLoS Negl Trop Dis. 2014 Jun 12;8(6):e2874. doi: 10.1371/journal.pntd.0002874. eCollection 2014 Jun. PLoS Negl Trop Dis. 2014. PMID: 24922480 Free PMC article.

MeSH terms

Substances